Anupam Rasayan India Limited, one of India’s leading custom synthesis and specialty chemical companies, has completed its third strategic acquisition by purchasing a 48.2% controlling stake in Bliss GVS Pharma Limited. The company paid Rs. 299 per share to finalize the transaction, successfully expanding its portfolio into the finished dosage formulations sector.

The transaction has been funded through a combination of a Rs. 300 crore term loan and approximately Rs. 1,450 crore raised through non-controlling, non-voting instruments from a group of financial investors led by Bain Capital and including Trust Group and Investec. The financing structure enables Anupam Rasayan to fund the acquisition while preserving balance-sheet capacity for future growth and expansion.

Anupam Rasayan has completed its acquisition of Bliss GVS Pharma via its wholly owned subsidiary, Mates Visa Consultancy. This milestone follows their initial May 23, 2026, definitive agreement and the subsequent fulfillment of the mandatory open offer process. Bliss GVS Pharma will now operate as a core component of Anupam Rasayan's expanding footprint across the pharmaceutical and specialty chemical sectors.

On the acquisition, Anand Desai, Managing Director of Anupam Rasayan India Ltd., said, “We are pleased to announce the successful completion of the acquisition of Bliss GVS Pharma. This transaction marks an important milestone in our long-term strategy to build a diversified, integrated and innovation-led global pharmaceutical platform.

The acquisition strengthens our presence in finished pharmaceutical formulations and complements Anupam Rasayan’s expertise in key starting materials, intermediates and specialty chemicals.

Combining our manufacturing and process chemistry capabilities with Bliss GVS Pharma’s formulation expertise, customer relationships, and market presence, we are well positioned to pursue forward integration, new product development, and geographic expansion.

We believe this integration will strengthen our capabilities, unlock meaningful operational and commercial synergies, and support sustainable, long-term value creation for all our  stakeholders.”

The acquisition provides access to Bliss GVS Pharma’s established portfolio of branded formulations, manufacturing infrastructure and presence across multiple therapeutic segments. It also creates opportunities for greater integration across Anupam Rasayan’s pharmaceutical value chain and strengthens its ability to participate across the journey from key starting materials and intermediates to finished formulations.